AAIC 2025 Abstract
Results from a Human Factor Study Supporting Safe and Effective Use of the Lecanemab Subcutaneous Autoinjector
Trial in peopleInterventions
Papers by Erica M. Andreozzi
4 results
- AAIC 2025 Abstract
Baseline Participant Characteristics in the DIAN‐TU‐001 Trial
Trial in peoplePopulations - AAIC 2025 Abstract
Subcutaneous Lecanemab: Potential Benefits and Place in Therapy
Trial in peopleInterventions - AAIC 2025 Abstract
Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 Trial
Trial in peopleInterventions